Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia
- PMID: 33974910
- PMCID: PMC8064868
- DOI: 10.1016/j.cell.2021.04.033
Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia
Abstract
Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is initiated by binding of the viral Spike protein to host receptor angiotensin-converting enzyme 2 (ACE2), followed by fusion of viral and host membranes. Although antibodies that block this interaction are in emergency use as early coronavirus disease 2019 (COVID-19) therapies, the precise determinants of neutralization potency remain unknown. We discovered a series of antibodies that potently block ACE2 binding but exhibit divergent neutralization efficacy against the live virus. Strikingly, these neutralizing antibodies can inhibit or enhance Spike-mediated membrane fusion and formation of syncytia, which are associated with chronic tissue damage in individuals with COVID-19. As revealed by cryoelectron microscopy, multiple structures of Spike-antibody complexes have distinct binding modes that not only block ACE2 binding but also alter the Spike protein conformational cycle triggered by ACE2 binding. We show that stabilization of different Spike conformations leads to modulation of Spike-mediated membrane fusion with profound implications for COVID-19 pathology and immunity.
Keywords: COVID-19; SARS-CoV; SARS-CoV-2; Spike protein; coronavirus; phage display; receptor binding domain (RBD); recombinant monoclonal antibody; syncytia.
Copyright © 2021 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests B.W., W.-H.L., C.-W.H., Y.H., P.M.L.N., E.Z.X.N., H.C.T., C.Y.L., R.A.M., M.K.S., F.J.T., Y.Y.C.Y., and C.-I.W. are listed as inventors of a filed patent for all 27 monoclonal antibodies mentioned in this manuscript.
Figures













Similar articles
-
Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.Microbiol Spectr. 2021 Oct 31;9(2):e0135221. doi: 10.1128/Spectrum.01352-21. Epub 2021 Oct 13. Microbiol Spectr. 2021. PMID: 34643438 Free PMC article.
-
Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies.Structure. 2021 Jul 1;29(7):655-663.e4. doi: 10.1016/j.str.2021.05.014. Epub 2021 Jun 9. Structure. 2021. PMID: 34111408 Free PMC article.
-
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies.Nature. 2020 Dec;588(7839):682-687. doi: 10.1038/s41586-020-2852-1. Epub 2020 Oct 12. Nature. 2020. PMID: 33045718 Free PMC article.
-
Structural basis of severe acute respiratory syndrome coronavirus 2 infection.Curr Opin HIV AIDS. 2021 Jan;16(1):74-81. doi: 10.1097/COH.0000000000000658. Curr Opin HIV AIDS. 2021. PMID: 33186231 Review.
-
Mutations in the SARS-CoV-2 spike receptor binding domain and their delicate balance between ACE2 affinity and antibody evasion.Protein Cell. 2024 May 28;15(6):403-418. doi: 10.1093/procel/pwae007. Protein Cell. 2024. PMID: 38442025 Free PMC article. Review.
Cited by
-
Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617.bioRxiv [Preprint]. 2021 Dec 24:2021.12.21.473733. doi: 10.1101/2021.12.21.473733. bioRxiv. 2021. Update in: Nat Commun. 2022 Mar 28;13(1):1638. doi: 10.1038/s41467-022-29288-3. PMID: 34981065 Free PMC article. Updated. Preprint.
-
ACE2 and Innate Immunity in the Regulation of SARS-CoV-2-Induced Acute Lung Injury: A Review.Int J Mol Sci. 2021 Oct 25;22(21):11483. doi: 10.3390/ijms222111483. Int J Mol Sci. 2021. PMID: 34768911 Free PMC article. Review.
-
Nanoscopic Assessment of Anti-SARS-CoV-2 Spike Neutralizing Antibody Using High-Speed AFM.Nano Lett. 2023 Jan 25;23(2):619-628. doi: 10.1021/acs.nanolett.2c04270. Epub 2023 Jan 15. Nano Lett. 2023. PMID: 36641798 Free PMC article.
-
SARS-CoV-2 Syncytium under the Radar: Molecular Insights of the Spike-Induced Syncytia and Potential Strategies to Limit SARS-CoV-2 Replication.J Clin Med. 2023 Sep 20;12(18):6079. doi: 10.3390/jcm12186079. J Clin Med. 2023. PMID: 37763019 Free PMC article. Review.
-
Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617.Nat Commun. 2022 Mar 28;13(1):1638. doi: 10.1038/s41467-022-29288-3. Nat Commun. 2022. PMID: 35347138 Free PMC article.
References
-
- Burton D.R., Saphire E.O., Parren P.W. A model for neutralization of viruses based on antibody coating of the virion surface. Curr. Top. Microbiol. Immunol. 2001;260:109–143. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous